(Q59051193)

1

0 references

Kazutaka Sumita

2

0 references

Hirofumi Yoshino

3

0 references

Dillon Chen

4

0 references

Jumpei Terakawa

5

0 references

Takiko Daikoku

6

0 references

Satoshi Kofuji

7

0 references

Richard Curry

8

0 references

Trisha M. Wise-Draper

9

0 references

Ronald E. Warnick

10

0 references

Jessica Guarnaschelli

11

0 references

Atsuo T. Sasaki

Journal of Cancer Research

12

0 references

publication date

2014

0 references

published in

0 references

volume

2014

0 references

page(s)

1-12

0 references

copyright license

Creative Commons Attribution 3.0 Unported

start time

7 July 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Targeting the phosphoinositide 3-kinase pathway in cancer

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Regulation of cancer cell metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Targeting the PI3K-AKT-mTOR signaling network in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Mechanisms of mTOR inhibitor resistance in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Physiological concentrations of purines and pyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

The molecular determinants of de novo nucleotide biosynthesis in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Overexpression of Inosine 5′-Monophosphate Dehydrogenase Type II Mediates Chemoresistance to Human Osteosarcoma Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Monitoring of inosine monophosphate dehydrogenase activity in mononuclear cells of children with acute lymphoblastic leukemia: enzymological and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Regulation of inosine monophosphate dehydrogenase type I and type II isoforms in human lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Why do mutations in the ubiquitously expressed housekeeping gene IMPDH1 cause retina-specific photoreceptor degeneration?

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Prognostic significance of drug-regulated genes in high-grade osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Modulation of IMPDH2, survivin, topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Proteome analysis and morphological studies reveal multiple effects of the immunosuppressive drug mycophenolic acid specifically resulting from guanylic nucleotide depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Regulation of a eukaryotic gene by GTP-dependent start site selection and transcription attenuation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Mycophenolic acid-induced replication arrest, differentiation markers and cell death of androgen-independent prostate cancer cells DU145.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Potential role of mycophenolate mofetil in the management of neuroblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Mycophenolic Acid overcomes imatinib and nilotinib resistance of chronic myeloid leukemia cells by apoptosis or a senescent-like cell cycle arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Mycophenolic acid induces adipocyte-like differentiation and reversal of malignancy of breast cancer cells partly through PPARγ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Mycophenolate mofetil inhibits tumor growth and angiogenesis in vitro but has variable antitumor effects in vivo, possibly related to bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

The immunosuppressive drug mycophenolate mofetil impairs the adhesion capacity of gastrointestinal tumour cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Molecular mechanisms of the antiangiogenic and antitumor effects of mycophenolic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Everolimus and mycophenolate mofetil sensitize human pancreatic cancer cells to gemcitabine in vitro: a novel adjunct to standard chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Mycophenolate mofetil and its mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Mycophenolate mofetil increases adhesion capacity of tumor cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Mycophenolic acid inhibits migration and invasion of gastric cancer cells via multiple molecular pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Collagen I promotes metastasis in pancreatic cancer by activating c-Jun NH(2)-terminal kinase 1 and up-regulating N-cadherin expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

A preclinical and clinical study of mycophenolate mofetil in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Reduction of gastrointestinal complications in renal graft recipients after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Enteric-coated mycophenolate sodium: results of two pivotal global multicenter trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Pharmacokinetics of mycophenolic acid in renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Malignancy after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Combined introduction of anti-IL2 receptor antibodies, mycophenolic acid and tacrolimus: effect on malignancies after renal transplantation in a single-centre retrospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Addition of MMF to dual immunosuppression does not increase the risk of malignant short-term death after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Central nervous system lymphoma associated with mycophenolate mofetil in lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Ribavirin, tiazofurin, and selenazofurin: mononucleotides and nicotinamide adenine dinucleotide analogues. Synthesis, structure, and interactions with IMP dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Induction of erythroid differentiation and modulation of gene expression by tiazofurin in K-562 leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part I. In vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Benzamide riboside induced mitochondrial mediated apoptosis in human lung cancer H520 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Antiproliferative effects of AVN944, a novel inosine 5-monophosphate dehydrogenase inhibitor, in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

A phase I dose-ranging study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of AVN944, an IMPDH inhibitor, in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401

Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F423401